Stocks · News reference
Filed: 2026-09-22 AccNo: 0001437749-26-030900 Size: 483 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aytu BioPharma reported a Q4 loss of $0.05 per share, beating consensus estimates of -$0.22 loss, representing a 77.27% earnings surprise. The company posted revenues of $16.11 million, surpassing consensus by 39.45%. However, the stock has underperformed the market, down 18.3% year-to-date versus the S&P 500's 13.4% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
On Tuesday, Aytu BioPharma (NASDAQ:AYTU) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time
Aytu BioPharma (NASDAQ:AYTU) reported quarterly sales of $16.106 million which beat the analyst consensus estimate of $12.276 million by 31.20 percent. This is a 6.42 percent increase over sales of $15.135 million the